Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Esophagus Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions: 1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy? 2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?
Primary outcome measures
- pCR [Time frame: From enrollment to the end of surgery]
Secondary outcome measures (1)
- Non-Favorable Responses [Time frame: From enrollment to the end of surgery]
Eligibility criteria
Inclusion criteria
- Patients with histologically confirmed esophageal cancer based on biopsy results;
- Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;
- Patients who received neoadjuvant chemoimmunotherapy;
- Patients with complete imaging data before and after neoadjuvant treatment.
Exclusion criteria
- Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;
- Patients with missing or poor-quality CT images;
- Patients with concurrent malignancies other than esophageal cancer;
- Patients with incomplete clinical data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The Second Xiangya Hospital of Central South University — Changsha
Identifiers
NCT: NCT07063901 · LYF20250118